

CalciviD

Affecting the lives of millions of people in the world, osteoporosis gradually turned into a public health issue in the last few decades. The progress of osteoporosis is irreversible, however, calcium and vitamin D intake – started in time – can reduce the likelihood of developing osteoporosis. Preexisting osteoporosis can also be slowed down with the combined application of a prescription medicine and calcium plus vitamin D, such as CalciviD.

Béres offers CalciviD for osteoporosis treatment.

CalciviD is an effective combination for the prevention and supplementary treatment of osteoporosis. It contains calcium, the most abundant constituent of bones, in high quantities and vitamin D3 that facilitates calcium absorption and incorporation into bones.



CalciviD

- Prevention and treatment of vitamin D and calcium deficiency in elderly.
- Vitamin D and calcium supplement as an adjunct to specific osteoporosis treatment of patients who are at risk of vitamin D and calcium deficiency.

Registration category	OTC medicinal product
Pharmaceutical form	film-coated tablet
SKU	30x, 60x
Package	blister

Dosage:

Adults and elderly

One tablet twice a day.

Dose reduction should be considered as necessary following the monitoring of calcium levels.

Active Substances	Qty /tbl
Calcium	600 mg
Vitamin D3	400 IU

The **Mutual Recognition Process** (MRP) for the approval of Béres CalciviD product has been completed throughout 9 EU Concerned Member States so far:

- Hungary
- Bulgaria
- Czech Republic
- Estonia
- Latvia
- Poland
- Romania
- Slovakia
- United Kingdom

MRP in additional countries may be finalized within 6 months upon request.

Contact

Béres Pharmaceuticals Ltd.

Address: Hungary, 1037 Budapest, Mikoviny u. 2-4.

www.beres.hu

Export Management:

Dr. Ádám Hornyánszky

Phone: +36-1-430-5585

hornyanszky.adam@beres.hu